Clinical trial
Research Study Using Recombinant Human Insulin-Like Growth Factor-1/Recombinant…
NCT00351221 · Insmed Incorporated, Industry · Terminated
Key facts
| NCT number | NCT00351221 |
|---|---|
| Title | Research Study Using Recombinant Human Insulin-Like Growth Factor-1/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 for Children With Noonan Syndrome |
| Official title | A Phase 2, Open-Label, Multicenter, Clinical Trial to Evaluate the Pharmacokinetics, Safety and Efficacy of Recombinant Human Insulin-Like Growth Factor-1/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 in Children With Growth Failure Due to Noonan Syndrome |
| Lead sponsor | Insmed Incorporated, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Noonan Syndrome |
| Intervention type | Drug |
| Interventions | rhIGF-1/rhIGFBP-3 |
| Enrollment | 24 |
| First posted | Jul 12, 2006 |
| Last update posted | Mar 30, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: